Subsequently, significant survival differences were observed in patients with bladder urothelial carcinoma (P = .0083), breast invasive carcinoma (P = .0041), cervical squamous cell carcinoma and endocervical adenocarcinoma (P = .015), kidney renal clear cell carcinoma (P = .019), mesothelioma (P = .0054), rectum adenocarcinoma (P = .019), and THCA (P = .043) between the HEG and LEG of PTPN11 (Fig. 1B). This evidence concerns the gene PTPN11 and bladder transitional cell carcinoma.